Now on ScienceBlogs: Oldest Human-Made Object in Space

ScienceBlogs Book Club: Inside the Outbreaks

Neuron Culture

David Dobbs on science, nature, and culture.

Search

Profile

dobbspic I write articles on science, medicine, nature, culture and other matters for the New York Times Magazine, The Atlantic, Slate, National Geographic, Scientific American Mind, and other publications, and am working on my fourth book, The Orchid and the Dandelion, which expands on my recent December 2009 Atlantic article. In August 2010, I'll be moving to London for a year to work on the book. I'll also serve as a senior fellow at City University London's MA science journalism program.

You're encouraged to check out my third book Reef Madness: Charles Darwin, Alexander Agassiz, and the Meaning of Coral, which traces the strangest but most forgotten controversy in Darwin's career; subscribe to Neuron Culture by email; see more of my work at my main website; or track Twitter feed, my Google Reader shared items, or my Tumblr log, which gets it all.

Twitterature>

Twitter Updates

    Follow me on Twitter

    Worth Noting

    Recent Posts

    Recent Comments

    Categories

    « Misdiagnosing the live and the dead | Main | Quick dip: Bonobo teeth, flu vaccines, death-of-midlist 3.0, death of the uninsured, and gory films »

    Much ado about swine flu

    Posted on: September 22, 2009 9:05 AM, by David Dobbs


    631D00A6-9C03-4CB5-89A6-186D44D23F77.jpg

    The swine flu triage tent at Dell's Children's Medical Center, in Austin, Texas
    photo: Ralph Barerra, Austin American-Statesman

    I can't keep up with the flu news. (If you want to, best single bet -- the wide net -- is Avian Flu Diary.) But as the World Health Organisation meets in Hong-Kong to discuss, among other things, swine flu, here are a couple that make good follow-ups to my Slate piece on how adjuvants gobble up vaccine antigen supply:

    WHO pushes for worldwide swine flu vaccinations (hoping to vaccinate 3 billion) -- despite that overall supply will fall short .

    The U.S. (and some other developed countries) agree to donate 10 percent of their supply to the effort.

    The first reports of vaccine trials in children give mixed results: kids 10-17 seem (like adults in the first two trials reported) to respond well to the vaccine, with most developing antibody responses likely to confer immunity; but kids under 10 do not, and will probably require two doses spaced some time apart. This probably means most kids under 10 will be vulnerable to the virus for longer. For both this news and a meta-look at how unevenly it is reported, see Effect Measure's post of this morning.

    NB: Slate's Jack Shafer has a nice piece echoing Effect Measure's beef about the press being too upbeat on H1N1.

    And if you don't think this could get bad, consider that even at this early stage, Dell's Chidren's Medical Center, in Austin, is so swamped with flu patients that it has set up triage tents -- and is suffering staffing shortages in the ER.

    I've received a fair amount of mail about my Slate piece. (See Slate's Fray for a taste of the range.) I hope to finish a post following up more substantially soon.

    Share on Facebook
    Share on StumbleUpon
    Share on Facebook
    Find more posts in: Medicine & Health

    TrackBacks

    TrackBack URL for this entry: http://scienceblogs.com/mt/pings/120544

    Post a Comment

    (Email is required for authentication purposes only. On some blogs, comments are moderated for spam, so your comment may not appear immediately.)





    ScienceBlogs

    Search ScienceBlogs:

    Go to:

    Advertisement
    Follow ScienceBlogs on Twitter

    © 2006-2011 ScienceBlogs LLC. ScienceBlogs is a registered trademark of ScienceBlogs LLC. All rights reserved.